Use of response surface methodology for development of new microwell-based spectrophotometric method for determination of atrovastatin calcium in tablets

Chemistry Central Journal

Tanveer A Wani¹  Ajaz Ahmad³  Seema Zargar²  Nasr Y Khalil¹  Ibrahim A Darwish¹ 

[1] Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia

[2] Department of Biochemistry, College of Science, King Saud University, P.O. Box 22452, Riyadh, 11211, Saudi Arabia

[3] Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia

关键词: Tablets;    Optimization;    Validation;    Atorvastatin;    Response surface methodology;   

Others  :  788041
DOI  :  10.1186/1752-153X-6-134

 received in 2012-09-09, accepted in 2012-11-06,  发布年份 2012

【 摘 要 】

Background

Response surface methodology by Box–Behnken design employing the multivariate approach enables substantial improvement in the method development using fewer experiments, without wastage of large volumes of organic solvents, which leads to high analysis cost. This methodology has not been employed for development of a method for analysis of atorvastatin calcium (ATR-Ca).

Results

The present research study describes the use of in optimization and validation of a new microwell-based UV-Visible spectrophotometric method of for determination of ATR-Ca in its tablets. By the use of quadratic regression analysis, equations were developed to describe the behavior of the response as simultaneous functions of the selected independent variables. Accordingly, the optimum conditions were determined which included concentration of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), time of reaction and temperature. The absorbance of the colored-CT complex was measured at 460 nm by microwell-plate absorbance reader. The method was validated, in accordance with ICH guidelines for accuracy, precision, selectivity and linearity (r² = 0.9993) over the concentration range of 20–200 μg/ml. The assay was successfully applied to the analysis of ATR-Ca in its pharmaceutical dosage forms with good accuracy and precision.

Conclusion

The assay described herein has great practical value in the routine analysis of ATR-Ca in quality control laboratories, as it has high throughput property, consumes minimum volume of organic solvent thus it offers the reduction in the exposures of the analysts to the toxic effects of organic solvents, environmentally friendly "Green" approach) and reduction in the analysis cost by 50-fold.

【 授权许可】

   
2012 Wani et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA: Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002, 287:337-344.
• [2]Lea AP, Mc Tavish D: Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997, 53:828-847.
• [3]Ferreira SL, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC, da Silva EG, Portugal LA, dos Reis PS, Souza AS, dos Santos WN: Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta 2007, 597:179-186.
• [4]Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA: Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta 2008, 76:965-977.
• [5]Mason RL, Gunst RF, Hess JL: Statistical Design and Analysis of Experiments. Hoboken, NJ: Wiley; 2003:586.
• [6]Darwish IA, Abdine HH, Amer SM, Al-Rayes LI: Spectrophotometric study for the reaction between fluvoxamine and 1,2-naphthoquinone-4-sulphonate: Kinetic, mechanism and use for determination of fluvoxamine in its dosage forms. Spectrochim Acta A 2009, 72:897-902.
• [7]Ahmed S, Rasul A, Masood Z: Spectrophotometry in Pharmaceutical Analysis. Germany: LAP Lambert Academic Publishing; 2011.
• [8]Gorog S: Ultraviolet–visible spectrophotometry in pharmaceutical analysis. Boca Raton, FL: CRC Press; 1995.
• [9]Darwish IA, Wani TA, Khalil NY, Al-Shaikh AA, Al-Morshadi N: Development of a novel 96-microwell assay with high throughput for determination of olmesartanmedoxomil in its tablets. Chem Cent J 2012, 6:1. BioMed Central Full Text
• [10]Darwish IA, Wani TA, Khalil NY, Bakheit AH: Novel 96-microwell spectrophotometric assays with high throughput for determination of irbesartan in its tablets. Digest Journal of Nanomaterials and Biostructures 2012, 7:415-421.
• [11]Mishra P, Gupta A, Shah K: Simultaneous estimation of atorvastatin calcium and amlodipine besylate from tablets. Indian J Pharm Sci 2007, 69:831-833.
• [12]Khan MR, Jain D: Simultaneous spectrophotometric determination of atorvastatin calcium and amlodipine besylate in tablets. Indian J Pharm Sci 2006, 68:546-548.
• [13]Jadhav SD, Bhatia MS, Thamake SL, Pishawikar SA: Spectrophotometric assays for estimation of atorvastatin calcium from tablet dosage forms. Int J Pharm Tech Res 2010, 2:1948-1953.
• [14]Ashour S, Bahbouh M, Khateeb M: A novel use of oxidative coupling reactions for determination of some statins (cholesterol-lowering drugs) in pharmaceutical formulations. Spectrochim Acta A 2011, 78:913-917.
• [15]Saradhi SV, Rao GD, Srinivasu P, Venkatesh BSS: Visible spectrophotometric assay for the determination of a lipid lowering drug in pharmaceutical dosage forms. J Pure Appl Microbiol 2007, 1:313-315.
• [16]Nagaraju P, Gopal NV, Srinivas VDN, Padma SVN: Spectrophotometric assays for the determination of atorvastatin calcium in pure and its pharmaceutical dosage forms. Asian J Res Chem 2008, 1:64-66.
• [17]Erk N: Extractive spectrophotometric determination of atorvastatin in bulk and pharmaceutical formulations. Anal Lett 2003, 36:2699-2711.
• [18]Wani TA, Khalil NY, Abdel-Rahman HM, Darwish IA: Novel microwell-based spectrophotometric assay for determination of atorvastatin calcium in its pharmaceutical formulations. Chem Cent J 2011, 5:57. BioMed Central Full Text
• [19]Fidler AT, Baker EL, Letz RE: Neurobehavioural effects of occupational exposure to organic solvents among construction painters. Br J Ind Med 1987, 44:292-308.
• [20]Wennborg H, Bonde JP, Stenbeck M, Olsen J: Adverse reproduction outcomes among employees working in biomedical research laboratories. Scand J Work Environ Health 2002, 28:5-11.
• [21]Lindbohm ML, Taskinen H, Sallmén M, Hemminki K: Spontaneous abortions among women exposed to organic solvents. Am J Ind Med 1990, 17:449-463.
• [22]Wennborg H, Bodin L, Vainio H, Axelsson G: Pregnancy outcome of personnel in Swedish biomedical research laboratories. J Occup Environ Med 2000, 42:438-446.
• [23]Kristensen P, Hilt B, Svendsen K, Grimsrud TK: Incidence of lymphohaematopoietic cancer at a university laboratory: a cluster investigation. Eur J Epidemiol 2008, 23:11-15.
• [24]Darwish IA: Analytical study for the charge transfer complexes of losartan potassium. Anal Chim Acta 2005, 549:212-220.
• [25]Askal HF: Spectrophotometric study of the charge transfer complexes of some pharmaceutical butyrophenones. Talanta 1997, 44:1749-1755.
• [26]Darwish IA, Refaat IH: Spectrophotometric analysis of selective serotonin reuptake inhibitors based on formation of charge-transfer complexes with tetracyanoquinodimethane and chloranilic acid. J AOAC Int 2006, 89:326-333.
• [27]Darwish IA, Mahmoud AM, Al-Majed AR: A novel analytical approach for reducing the consumption of organic solvents in the charge transfer-based spectrophotometric analysis: application in the analysis of certain antihypertensive drugs. Acta Pharm 2010, 60:493-501.
• [28]Taha A, Rücker G: Utility of pi-acceptors in alkaloid assay. Arch Pharm (Weinheim) 1977, 310:485-494.
• [29]ICH, Q2B Validation of Analytical Procedures: Methodology International Conference on Harmonization. Geneva: The International Conference on Harmonization; 1996.
• [30]The United States Pharmacopeia 24, The National Formulary 19. Rockville: United States Pharmacopeial Convention, Inc; 2008.